PRADX and glioblastoma: To seek new treatment modalities for GBM patients with a high PRADX level in vivo, we constructed intracranial xenograft models with PRADX overexpressed TBD0220 cells and tested the efficiency of both the monotherapies and combination therapy with Triacsin C (30mg/kg/d) and Etomoxir (30mg/kg/d).